Fibrogen acknowledged Tuesday that the company has been touting false heart-safety data for its experimental anemia pill for at least two years — a shocking revelation that raises even more questions about the drug’s approvability.
Shares of Fibrogen fell 27% to $25 in Tuesday’s after-hours trading session as investors questioned the credibility of the company’s management team and mulled the ramifications of revised heart-safety data that may no longer be strong enough to pass muster with the Food and Drug Administration.
About the Author Reprints
